Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE001 T Cell Injection for KRAS G12V Mutated Solid Tumors
NCT06545201Phase 1Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Aug 2024
- Primary completion
- Apr 2026
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RE001 T cell in solid tumor, sponsored by Henan Cancer Hospital. Primary endpoint: Overall Response Rate. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
RE001 T cell
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06545201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06545201.